StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
bluebird bio (BLUE) to Charge $2.8M for Fda-Cleared Blood Disorder Therapy - Bloomberg
August 17, 2022 1:54 PM
bluebird bio (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Next Articles
bluebird bio (BLUE) Resumes Trading, Up 20%
August 17, 2022 2:30 PM
bluebird bio (BLUE) to Resume Trading at 2:30 p.m.
August 17, 2022 2:10 PM
bluebird bio (BLUE) Confirms FDA Approval of ZYNTEGLO Gene Therapy
August 17, 2022 2:05 PM
FDA Approves bluebird bio's (BLUE) Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions
August 17, 2022 1:40 PM
bluebird bio (BLUE) Halted, News Pending
August 17, 2022 12:41 PM
